Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ZOM 
Zomedica Pharmaceuticals Corp (ZOM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: ZOM (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -59.14% | Avg. Invested days 19 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 147.60M USD | Price to earnings Ratio - | 1Y Target Price 0.25 |
Price to earnings Ratio - | 1Y Target Price 0.25 | ||
Volume (30-day avg) 10693350 | Beta 1.06 | 52 Weeks Range 0.03 - 0.20 | Updated Date 02/23/2025 |
52 Weeks Range 0.03 - 0.20 | Updated Date 02/23/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.06 |
Earnings Date
Report Date 2025-03-31 | When Before Market | Estimate - | Actual - |
Profitability
Profit Margin -214.7% | Operating Margin (TTM) -147.5% |
Management Effectiveness
Return on Assets (TTM) -9.29% | Return on Equity (TTM) -23.92% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -12701920 | Price to Sales(TTM) 3.57 |
Enterprise Value -12701920 | Price to Sales(TTM) 3.57 | ||
Enterprise Value to Revenue 2.01 | Enterprise Value to EBITDA -7.19 | Shares Outstanding 997950016 | Shares Floating 961507015 |
Shares Outstanding 997950016 | Shares Floating 961507015 | ||
Percent Insiders 1.78 | Percent Institutions 8.33 |
Analyst Ratings
Rating 5 | Target Price 0.25 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Zomedica Pharmaceuticals Corp
Company Overview
History and Background
Zomedica Pharmaceuticals Corp was founded in 2013. It focuses on developing and commercializing innovative products for the unmet needs of clinical veterinarians.
Core Business Areas
- Diagnostics: Development and commercialization of diagnostic products and platforms for use in veterinary clinics. Products include TRUFORMA and VetGuardian.
- Therapeutics: Development of pharmaceutical products focused on addressing unmet clinical needs in the veterinary market.
- Consumables: Providing consumable supplies and equipment that are needed to facilitate the function of installed instruments. A recurring revenue model.
Leadership and Structure
Larry Heaton is the Chief Executive Officer. The company has a board of directors and operates with functional departments like R&D, sales, and marketing.
Top Products and Market Share
Key Offerings
- TRUFORMA: A point-of-care diagnostic platform utilizing Bulk Acoustic Wave (BAW) sensor technology for immunoassay and clinical chemistry testing in animals. Zomedica has recently obtained the full rights to TRUFORMA and has shifted from a distributor to a product developer and manufacturer. Limited Market share data available, competition includes IDEXX Laboratories (IDXX) and Heska (HSKA).
- VetGuardian: A wireless vital signs monitoring system designed for veterinary patients undergoing anesthesia or in critical care. Allows remote patient monitoring. Zomedica acquired this product through an acquisition. Market share data not publicly available. Competitors include Welch Allyn (Hillrom- now Baxter BAX) and Masimo (MASI).
Market Dynamics
Industry Overview
The veterinary diagnostics and therapeutics market is growing due to increasing pet ownership and rising spending on pet healthcare. Point-of-care diagnostics are gaining traction for faster results.
Positioning
Zomedica is positioned as a provider of innovative point-of-care diagnostic and monitoring solutions for the veterinary market. Their focus is on unmet needs with proprietary technology.
Total Addressable Market (TAM)
The global veterinary healthcare market is estimated to be in the tens of billions of dollars. Zomedica is focusing on capturing a portion of the point-of-care diagnostics and monitoring segments. TAM expected to be between $5 and $10 billion by 2027, according to multiple sources.
Upturn SWOT Analysis
Strengths
- Proprietary TRUFORMA BAW technology
- Focus on point-of-care diagnostics
- Recurring revenue from consumables
- Recent acquisition to expand product portfolio and internalize manufacturing
Weaknesses
- Limited sales and marketing infrastructure
- Dependence on a few key products
- Relatively small market capitalization
- History of Net Losses
Opportunities
- Expanding product line through internal development or acquisition
- Increasing market penetration in veterinary clinics
- Strategic partnerships with distributors or veterinary hospitals
- Capitalizing on telehealth and remote monitoring trends
Threats
- Competition from established players like IDEXX and Zoetis
- Regulatory hurdles for new product approvals
- Economic downturn affecting pet owner spending
- Product development delays or failures
Competitors and Market Share
Key Competitors
- IDXX
- ZTS
- BXR
- MASI
Competitive Landscape
Zomedica is a smaller player in a competitive market dominated by larger, more established companies. Its competitive advantage lies in its proprietary technology and focus on unmet needs. Zomedica will continue to face headwinds until it is able to establish a more dominant market presence.
Major Acquisitions
Pulse Veterinary Technologies
- Year: 2021
- Acquisition Price (USD millions): 70.9
- Strategic Rationale: Expanded Zomedica's product portfolio with the addition of the Assisi Loop, a therapeutic device for pain management and tissue healing in animals.
Revo Squared
- Year: 2023
- Acquisition Price (USD millions): 17.5
- Strategic Rationale: Acquisition of VetGuardian and related technologies.
Growth Trajectory and Initiatives
Historical Growth: Zomedica has experienced rapid revenue growth in recent years as it began commercializing its products. However, it is still in the early stages of its growth trajectory.
Future Projections: Analyst estimates project continued revenue growth as Zomedica expands its product portfolio and market reach. Profitability is expected to improve as the company achieves greater economies of scale.
Recent Initiatives: Recent initiatives include the acquisition of VetGuardian, full rights to TRUFORMA, and expansion of the sales force.
Summary
Zomedica is a small company with innovative technology but is still facing challenges. It has good growth potential through acquisitions of new products and internal product development. It needs to increase its sales and marketing efforts to gain market share. Intense competition from established players will continue to be a factor. Ultimately, the company needs to become profitable.
Similar Companies
BKR
Baker Hughes Co
BKR
Baker Hughes Co
IDXX
IDEXX Laboratories Inc
IDXX
IDEXX Laboratories Inc
MASI
Masimo Corporation
MASI
Masimo Corporation
ZTS
Zoetis Inc
ZTS
Zoetis Inc
Sources and Disclaimers
Data Sources:
- Company filings (10-K, 10-Q)
- Company website
- Analyst reports
- Industry publications
- Press Releases
- Market Data Forecast reports
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It is not financial advice. Investment decisions should be based on your own due diligence and assessment of risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Zomedica Pharmaceuticals Corp
Exchange NYSE MKT | Headquaters Ann Arbor, MI, United States | ||
IPO Launch date 2016-07-29 | President, CEO & Director Mr. Larry C. Heaton II | ||
Sector Healthcare | Industry Medical Devices | Full time employees 144 | Website https://www.zomedica.com |
Full time employees 144 | Website https://www.zomedica.com | ||
Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital signs remote monitoring system. It also provides therapeutic products, including PulseVet electrohydraulic shockwave therapy platform; and Assisi Loop line of products, including the Assisi Loop, Assisi Loop Lounge, and DentaLoop devices that treat pain and inflammation through delivery of targeted pulsed electromagnetic field focused energy. The company has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for the development of a novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. is headquartered in Ann Arbor, Michigan.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.